Growth of Human Tumor Cells in Macroporous Microcarriers Results in p53-Independent, Decreased Cisplatin Sensitivity Relative to Monolayers

BARRY J. MAURER,1,2 MICHAEL A. INHAT,1 CINDY MORGAN, JANICE PULLMAN, CRAIG O’BRIEN, STEVEN W. JOHNSON, JANET S. RASEY, and MARILYN M. CORNWELL1

Program of Molecular Pharmacology, Fred Hutchinson Cancer Research Center, Seattle, Washington (B.J.M., M.A.I., C.M., J.P., C.O., M.M.C.); the Fox Chase Cancer Center, Philadelphia, Pennsylvania (S.W.J.); and Department of Radiation Oncology, University of Washington, Seattle, Washington (J.S.R.)

Received August 27, 1998; accepted February 12, 1999 This paper is available online at http://www.molpharm.org

ABSTRACT

Multicellular contact has been shown to influence the in vitro sensitivity of cells to drug treatment. We investigated the use of macroporous gelatin microcarriers, CultiSpher-G, as a convenient laboratory system for the molecular analysis of this “contact effect.” We determined that human A549 cells can be grown in CultiSpheres with growth and cell cycle parameters similar to those of monolayers. In addition, cells in CultiSpheres express less p27/kip1, an indicator of cell cycle arrest, than equivalent cells in monolayers. When treated with drugs, A549 cells grown in CultiSpheres or monolayers accumulate equivalent amounts of platinum-DNA adducts and similar amounts of doxorubicin. Moreover, A549 and KB-3-1 cells in CultiSpheres have significantly decreased sensitivity to cis-platinum(II)diammine dichloride (cisplatin), 4-hydroperoxycyclophosphamide, doxorubicin, and paclitaxel (taxol) compared with cells in monolayers when assayed by cloningogenic survival. Cisplatin treatment in monolayers or CultiSpheres did not result in apoptotic cell death. In contrast, paclitaxel caused a significant amount of sub-G0, DNA, an indicator of apoptosis, which was diminished when cells were grown in CultiSpheres compared with monolayers. When grown in CultiSpheres, cells with abrogated p53 function (A549/16E6 and NCI-H1299) were less sensitive to cisplatin than the corresponding monolayer cells, indicating that the decrease in sensitivity is p53 independent. Taken together, the data suggest that CultiSpher-G microcarriers are a useful in vitro system to examine the effects of three-dimensional cell contact on drug sensitivity of human tumor cells.

Three-dimensional intercellular contact in vitro influences the relative sensitivity of cells to both radiation and drug treatment, a phenomenon generally known as the “contact effect” (Sutherland et al., 1979, 1980; Rasey, 1984; Olive and Durand, 1994; Sakata et al., 1994). Several three-dimensional in vitro culture systems have been used to investigate the effect of intercellular contact on drug sensitivity (Vescio et al., 1991; Hoffman, 1993; Casciari et al., 1997), with most studies using multicellular spheroids (Twemtyan, 1980; Sutherland, 1988; Olive et al., 1993; St. Croix et al., 1996b). Although this “contact effect” has been extensively studied over the last 20 years, the molecular determinants of this effect have just begun to be identified. This can be attributed, in part, to the difficulty of separating the effects of cell-cell contact from gradients of drug penetration, nutrients, oxygen, pH, and cell cycling (Durand, 1990; Erlichman and Wu, 1992; Ramachandran et al., 1995).

Recently, we characterized the use of CultiSpher-G (Hy-Clone Laboratories, Logan, UT), macroporous porcine gelatin microcarriers, as a model cell culture system for drug sensitivity studies. These gelatin “sponges” with their variegated surface and large internal channels allow cell growth on the surface and within the bead. Cells growing in CultiSpheres histologically demonstrate significant three-dimensional contact without central necrosis, lack edge-to-center gradients of proliferation by [3H]thymidine autoradiography, and give no indication of a hypoxic fraction on radiation-response curves (Rasey et al., 1996). We also documented that in optimal

ABBREVIATIONS: 4-HC, 4-hydroperoxycyclophosphamide; cisplatin, cis-platinum(II)diammine dichloride; Pt-DNA, platinum-DNA; TBST, 10 mM Tris-HCl, pH 8, 150 mM NaCl, 0.5% Tween 20, p27, p27/kip1; MTS, 3-(4,5-dimethylthiazol-2-y)-5-(3-carboxy methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium.
cultur e conditions, CultiSphers can be used to produce populations of cells with extensive cell-cell contact whose cell cycling profiles and doubling times are similar to those of monolayers of the same cell type (Rasey et al., 1996).

To determine whether a “contact effect” might be elicited by growth of tumor cells in CultiSpheres, we used four common chemotherapeutic agents eliciting their cytotoxicity through different mechanisms of action: 4-hydroperoxycyclophosphamide (4-HC), the activated analog of cyclophosphamide, paclitaxel (taxol), doxorubicin, and cisplatinum (II) diammine dichloride (cispitant). Cisplatin has the advantage of producing readily detectable platinum-DNA (Pt-DNA) adducts, and doxorubicin is epifluorescent, characteristics that can be used to determine the equivalency of drug treatments.

In the current study, we examined the drug sensitivity of isogenic cells, differing only by growth in CultiSpheres or in monolayers on porcine gelatin-coated plastic. We report that growth of the A549 human lung tumor cell line in CultiSpheres caused a decreased sensitivity to cisplatin, 4-HC, paclitaxel, and doxorubicin by clonogenic survival assay compared with monolayer controls. This was observed under conditions in which cells in both growth modes had similar cell cycle profiles and accumulated similar amounts of drug.

In addition, we report that growth of two other independently derived tumor cell lines (KB-3-1 and NCI-H1299) in CultiSpheres decreased their sensitivity to cisplatin. Finally, we report that decreased sensitivity to cisplatin of A549 and NCI-H1299 cells grown in CultiSpheres was p53 independent.

**Experimental Procedures**

**Materials.** All chemicals were purchased from Sigma Chemical Co. (St. Louis, MO) unless otherwise noted. Culture media was prepared in-house from powder (Gibco-BRL, Gaithersburg, MD) and media additives were from Gibco-BRL or Atlanta Biologicals (Norcross, GA), except serum, which was from HyClone. CultiSpher-G gelatin microcarriers (mean diameter = 220 µm, range 170–270 µm), for cell culture were obtained from HyClone Laboratories. 4-HC was a gift of S. Rowley, Fred Hutchinson Cancer Research Center (PHCRC) (Seattle, WA). Enhanced chemiluminescence Western blotting detection reagents were from Amersham (Arlington Heights, IL). Anti sera to human p27 were a generous gift of Jim Roberts (FHCRC; Polyak et al., 1994). Quantitative protein assay was by Bio-Rad (Hercules, CA). Puregene DNA isolation kits were from Gentra Systems (Minneapolis, MN).

**Cell Lines and Culture Conditions.** A549 cells, a p53 wild-type human lung carcinoma cell line (ATCC CCL-185; American Tissue Culture Collection, Rockville, MD) and transfected derivatives were maintained in monolayer culture in F/D medium plus 10% bovine calf serum (growth medium). A549 derivatives A549/LXSN and A549/16E6 contain the stably transfected LXSN retroviral vector or vector cDNA encoding the E6 protein of plus human papilloma virus strain 16, respectively (Russell et al., 1995). KB-3-1 cells, a human epithelial carcinoma derivative (ATCC CCL-17) (Akiyama et al., 1992) were maintained in monolayer culture in Dulbecco’s modified Eagle medium plus 5% bovine calf serum. NCI-H1299 cells (ATCC CRL-5803) were maintained in RPMI-1640 medium with 10% fetal bovine serum. All media were supplemented with penicillin (100 U/ml) and streptomycin (100 µg/ml) and 2 mM glutamine. Tissue culture plates were gelatin coated by treating each dish with 8 ml of 5 mg/ml gelatin (type A, porcine skin) in 0.05 N HCl for 1 h followed by rinsing three times with sterile water.

Monolayer cells were plated at 4 × 10^5 cells per 10 cm^2 on gelatin-coated plates and allowed to grow for 48 h before drug treatment. CultiSpher-G gelatin microcarriers were seeded by addition of a single cell suspension (5 × 10^6 log phase cells) to 30 ml medium per 0.1 g CultiSpheres in a siliconized spinner flask, agitated for 5 min, and then allowed to settle undisturbed for 2 h. The spinner was reagitated for an additional 5 min and allowed to settle for 2 h. CultiSpheres were removed, washed three times with growth medium to remove unattached cells, and replaced in the flask with 50 ml growth medium per 0.1 g CultiSpheres. The following day an additional 50 ml growth medium was added per 0.1 g CultiSpheres. Each day thereafter, the beads were allowed to settle briefly, then half the medium was removed and replaced. CultiSpher occupancy was monitored by staining an aliquot of beads with 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide, 500 µg/ml in growth medium, at 37°C, for 30 min before observation. Cell number per bead was quantitated by counting the number of beads in an aliquot in a gridded Petri dish, recovering and disaggregating the CultiSpheres as described below, and counting cells in a hemacytometer. CultiSpheres were treated with drugs when they reached 200 to 500 cells/bead, a density at which cells remained in log phase growth, with no evidence of non-cycling cells by flow cytometry, doubling time, and Ki67 analyses (data not shown). Cells in monolayers and CultiSpheres have similar cell cycle profiles under these conditions (Rasey et al., 1996).

**Histology.** For histological analysis, A549 cells were seeded and grown in CultiSpheres to an average of ~1000 cells/bead. CultiSpheres were fixed in neutral buffered formalin, embedded in paraffin, sectioned and stained with H&E as previously described (Rasey et al., 1996).

**Drug Treatment Conditions.** Monolayers or CultiSpheres were rinsed once with growth medium to remove detached cells and drug-containing medium was added at 37°C for one hour as noted. Care was taken to ensure equivalent drug exposure and harvesting conditions with cells grown as monolayers and in CultiSpheres. Five milliliters of drug-containing medium was used per 10 cm dish (~1.6 × 10^6 cells). Larger volumes of CultiSpheres were treated in 100- to 250-ml spinner flasks with a similar total drug-medium volume-to-cell ratio. For treatment of small aliquots, washed CultiSpheres were placed in drug-containing medium at similar drug-to-cell ratios in 6-cm^2 bacteriological dishes, so that cells did not attach, for 1 h with gentle agitation every 10 min. Both monolayer and CultiSpheres cells were then harvested using collagenase as per the clonogenic survival assay below. Cispitant was freshly prepared as a 1 mg/ml stock in PBS, sterile filtered, and appropriate dilutions made in growth medium at 37°C immediately before use. 4-HC stock (100 mg/ml) was freshly prepared in growth medium, sterile filtered, and diluted in medium for immediate use. Doxorubicin was prepared as a 5-mM stock in water and paclitaxel prepared as a 5-mM stock in dimethyl sulfoxide and further diluted in growth medium for immediate use. Cells were then drug treated, washed three to four times in growth medium to remove drug, and then resuspended to original volume with equal parts conditioned and fresh medium. Thereafter, half the medium of dishes or spinners was removed and replaced with fresh growth medium daily.

For cisplatin treatment of cells after release from CultiSpheres, cells were dissociated from CultiSpheres as described below, then plated at 4 × 10^5 or 2 × 10^5 cells per gelatin-coated 15-cm dish for 4 or 24 h, respectively, ensuring a density at treatment of approximately 4 × 10^4 cells per dish. After release from CultiSpheres and replating, the cells in monolayers at 4 and 24 h displayed normal monolayer morphology and could not be removed by agitation alone. Cells in monolayers were then treated with 10 µg/ml cisplatin.

For doxorubicin accumulation and clonogenic studies, A549 cells were grown on gelatin-coated dishes (2 × 10^5 cells/dish followed by 48 h growth) or in CultiSpheres (562 cells/bead) and were treated with various doses (clonogenic assay) or 5 µg/ml (110 µM for uptake studies) doxorubicin for 1 h at 37°C in growth medium. After 1 h, cells in CultiSpheres were released from beads with collagenase as described below. Cell suspensions were then washed in ice-cold PBS, collected by centrifugation, and kept on ice until analyzed by flow cytometry. To provide the same washing for cells in monolayers and...
CultiSpheres, monolayers were washed two times with PBS, incubated in drug-free growth medium for 1 h, then released from dishes with a 2-min trypsin treatment. Cell suspensions were then washed in ice-cold PBS, collected by centrifugation, and kept on ice until analyzed by flow cytometry. Under these conditions, efflux of drug is minimal in cells, such as A549, that do not express P-glycoprotein (Willingham et al., 1986).

**Clonogenic Survival Assay.** To determine cell survival after drug treatment, single cell suspensions from CultiSpheres and monolayers were prepared by collagenase. After drug treatment, cells in monolayers or CultiSpheres were washed three times with whole medium and once with Hank’s balanced salt solution. Gelatin-containing CultiSpheres were digested to release the cells by adding 1 ml of 800 U/ml collagenase in Hank’s balanced salt solution per 1 mg of CultiSpheres at 37°C for 1 h, with agitation every 10 min. Known numbers of cells were plated for standard colony-forming assay (3–6 plates per cell dilution, 3–5 dilutions per drug concentration) in 6-cm or 6-well plates. Dilutions with greater than 5 × 10⁶ cells/dish were plated in 10-cm dishes. Surviving fraction was calculated in reference to the plating efficiency of untreated controls (two separate triplicate controls per experiment). Plates were incubated undisrupted for 10 to 12 days. Surviving colonies were stained with 0.5% methylene blue in 50% ethanol, visualized on a Leica StereoZoom 4 dissecting microscope (Leica Inc., Deerfield, IL), and colonies of at least 50 cells on plates containing 50 to 150 colonies were scored as positive.

**Cisplatin-DNA Adduct Measurements.** CultiSpheres were seeded in 250-ml spinner flasks, allowed to grow to at least 50 cells on plates containing 50 to 150 colonies were scored as positive.

**Flow Cytometry.** For cell cycle analysis, samples of cell suspensions were fixed in 50% ethanol, then prepared for flow cytometry analysis by incubation in PBS containing 0.1% Triton-X100, 25 μg/ml propidium iodide, and 100 μg/ml RNase A for 30 min, 37°C. Cells were analyzed on a Becton Dickinson FACScan with CELLQuest (Becton Dickinson, San Jose, CA) and MultiCycle AV (Phoenix Flow Systems, San Diego, CA) analysis software. For doxorubicin accumulation analysis, cell volume was monitored by forward scatter and granularity by side scatter, respectively, and a single gate applied to all samples (under conditions in which over 95% of all cells were contained within the gate). The doxorubicin fluorescence distribution was measured in the gated population of cells by excitation at 488 nm and emission at 585 nm (Luk and Tannock, 1989). With this methodology the fluorescence of each cell and the distribution of fluorescence of the population of cells was measured as previously described (McGown et al., 1983). For each sample, a statistical marker spanning the single peak of fluorescence was used to calculate the mean fluorescence (CELLQuest cytometry analysis software). Greater than 96% of the total number of gated cells were included in the statistical analysis for each sample. To estimate the relative uptake of doxorubicin after 1 h of treatment (and 1 h of efflux), the mean fluorescence in the presence of doxorubicin was normalized to the mean fluorescence in the absence of doxorubicin.

**Immunoblot Analysis.** Cellular protein was prepared from collagenase-released cells that were washed once with cold PBS, then lysed on ice for 30 min in 1% Nonidet P-40 in PBS with 10 μg/ml leupeptin, 10 μg/ml aprotinin, 2 mM 4-(aminomethyl)benzene-sulfonyl fluoride, 10 mM sodium fluoride, and 5 mM sodium pyrophosphate. Samples were collected by centrifugation at 8200g for 30 min at 4°C, and the solubilized protein quantitated by the Bio-Rad protein assay. Samples were stored at −70°C. For immunoblotting, 40 μg protein/lane was electrophoresed in precast Bio-Rad Mini-Protein II 12% SDS-polyacrylamide gels and electrotransferred to 0.2-μm nitrocellulose membranes (Schleicher & Schuell, Keene, NH). Quantitation was confirmed visually with Coomassie blue staining after polyacrylamide gel electrophoresis. Membranes were blocked overnight in 10 mM Tris-HCl, pH 8; 150 mM NaCl; 0.5% Tween 20 (TBST) and 5% nonfat dry milk at 4°C. Membranes were then incubated in polyclonal antibody to p27/kip1 at 1:2000 in TBST with 5% nonfat dry milk for 1 h at room temperature, followed by 3 × 15 min washes in TBST with 5% nonfat dry milk at room temperature. Membranes were incubated with goat anti-rabbit antibody (Santa Cruz Biotechnologies, Santa Cruz, CA) at 1:15,000 for 1 h at room temperature in TBST with 5% nonfat dry milk, followed by two 15-min washes in TBST with 0.5% dry milk and three 15-min washes in TBST. The membrane was then incubated with the chemiluminescence reagent (Amersham) for 1 min, drained, and exposed to autoradiography film.

**Statistical Evaluation of Data.** Averages, S.D.s, and unpaired two-tailed student’s t-tests at the 95% confidence interval were performed using Prism 2.0 software (GraphPad Software, San Diego, CA).

**Results**

**CultiSpher Culture System.** We characterized a multicellular growth system, macroporous gelatin microcarrier beads called CultiSpher-G (Nikolai and Hu, 1992) to study the role that cell contact and matrix interactions play in determining the response of cells to chemotherapeutic agents (Rasey et al., 1996). Figure 1 shows a typical histological section through a population of CultiSpher beads seeded with A549 cells. Using the manufacturer’s suggested seeding conditions, a range of cell densities was observed. Some beads were not populated, some beads were sparsely populated (Fig. 1, A and B; ~100 cells/bead), whereas others were densely populated (Fig. 1, C and D; ~1000 cells/bead). In the beads that were populated, cells grew well on both the external and internal surfaces of the bead. There were areas of single cells or monolayer-like growth as well as areas of extensive cell-cell contact. Even at high cell/bead ratios, some beads were not occupied. Therefore, the number of cells/bead is an average measure of overall occupancy. Longer growth

![Fig. 1. Photomicrograph of histological section of A549 CultiSpheres after 5 days of growth. Cells were seeded in CultiSpheres and prepared for histology. A and B, sparsely occupied CultiSpheres; C and D, densely occupied CultiSpheres.](Image)
periods in CultiSphers resulted in an increase in areas of multicellular contact and decreased single cells (data not shown). Extensive cell-cell contact within beads occurred while channels were maintained for drug (Table 1 and see Results below) and nutrient access (Rasey et al., 1996).

Cell cycle distribution was evaluated relative to bead occupancy to assess the effect of extensive cell contact in CultiSphers. For both A549 and KB-3-1 cells grown as CultiSpheres, flow cytometric cell cycle analysis indicated that occupancies of over 800 cells per bead resulted in an increased G1 population compared with exponentially growing monolayers, suggesting that at greater than 800 cells/bead, some cells were exiting the cell cycle (data not shown). Occupancies of less than 200 to 400 cells per bead produced no significant change in G1 status (data not shown). Our previous studies suggested that release of cells from beads in culture contributed to an apparent difference in doubling time between monolayers and CultiSpheres (Rasey et al., 1996). To examine this question, cell cycle studies using a 1-h pulse of 2-bromo-5-deoxyuridine indicated by flow cytometry that the cell cycle transit time for untreated monolayers and CultiSpheres at 255 cells/bead were similar (data not shown). Thus, seeding and growth conditions that produced cell/bead ratios of 200 to 400 cells per bead, typically 3 to 5 days postseeding, were used for subsequent experiments because they yielded cultures with extensive cell contact, similar cell cycle transit, and log phase growth.

Cell contact has been shown to induce the expression of the cell cycle inhibitor p27/kip1, resulting in cell cycle arrest (Poljak et al., 1994). Expression of p27 has also been correlated with decreased drug sensitivity of a wide variety of human tumor cell lines grown as multicellular spheroids (St. Croix et al., 1996a). In contrast to these data, A549 monolayer and CultiSpher cultures expressed little p27 protein (Fig. 2, lanes 1 and 2, top and bottom panels) at the time of drug treatment (3–5 days postseeding), conditions in which cells in CultiSpheres formed extensive cell-cell contacts. Following a 1-h treatment with 10 μg/ml cisplatin and 72 h of recovery (Fig. 2, top panel, lanes 5 and 6; data not shown), cells in monolayers expressed increased levels of p27 relative to mock-treated samples. In contrast, 72 h following the same cisplatin treatment, cells in CultiSpheres (Fig. 2, bottom panel, lanes 5 and 6) expressed very little p27. These data indicate that under similar growth conditions used to prepare CultiSpher cultures for drug treatment, p27/kip1 is not extensively expressed.

Analysis of Chemotherapeutic Drug Sensitivity of Cells Grown in CultiSpher Culture. Relative sensitivities to clinically relevant concentrations of drugs were then determined by clonogenic survival assay (Fig. 3). A549 cells grown as CultiSpheres (Fig. 3A) were much less sensitive to cisplatin compared with A549 cells grown as monolayers, as indicated by an increased survival fraction. To determine whether the observed decrease in cellular drug sensitivity was drug-specific, A549 cells grown as monolayers and in CultiSpheres were exposed to clinically relevant concentrations of 4-HC or doxorubicin for 1 h or paclitaxel for 24 h and clonogenic cell survival determined. A549 cells in CultiSpheres were also less sensitive to 4-HC (Fig. 3B), paclitaxel (Fig. 3C), and doxorubicin (Fig. 3D) compared with A549 monolayers. To assess whether this phenomenon was cell type-specific, the cisplatin sensitivities of KB-3-1 cervical cancer cells grown as monolayers and in CultiSpheres were determined. The results demonstrate that KB-3-1 (Fig. 3E) cells were also less sensitive to cisplatin when grown in CultiSpheres than when grown in monolayer culture. Statistical analysis using Student’s t test at 15 μg/ml cisplatin showed significantly different survival fractions for cells grown as monolayers versus in CultiSpheres (P = .002 for A549 cells in Fig. 3A and P < .001 for KB-3–1 cells in Fig. 3E). Further analysis by t test showed significant differences in survival fractions of A549 monolayers versus CultiSpheres at 200 μg/ml 4-HC (P < .0001; Fig. 3B), 100 nM paclitaxel (P < .0001; Fig. 3C), and at 1 μM doxorubicin (P = .0009; Fig. 3D).

If the decreased sensitivity to cisplatin of cells grown in CultiSpheres is a consequence of multicellular growth, disruption of multicellular interactions before drug treatment might alter the sensitivity of the cells. To examine this possibility, cells from CultiSpheres were released and replated onto gelatin-coated dishes as monolayers for 4 or 24 h and then treated for 1 h with cisplatin. As shown in Fig. 3F, A549 cells grown in CultiSpheres and replated for 4 h before treatment with cisplatin exhibited the same dose-dependent sensitivity as cells treated in CultiSpheres. However, cells grown in CultiSpheres and then replated for 24 h before treatment exhibited the same reduction in dose-dependent sensitivity as cells grown as monolayers. These data are similar to results observed for alkylating agent treatment of cells released from spheroids (Kobayashi et al., 1993) and suggest that the multicellular contact effect observed when cells are grown in CultiSpheres persists for at least 4 h but is reversible by 24 h after multicellular growth is disrupted.

Analysis of Doxorubicin Accumulation and Cisplatin DNA Adduct Formation in A549 Cells Grown as Monolayers and in CultiSpheres. The decreased sensitivity of cells in CultiSpheres might be explained by decreased drug accumulation or by lower drug concentration in a subset of cells. This possibility was examined using two methods. First, flow cytometry was used to determine doxorubicin accumulation and distribution within the cell population of monolayer and CultiSpher A549 cultures. Doxorubicin was chosen because it has been shown that treatment of cells grown as multicellular spheroids results in large doxorubicin concentration gradients, and thus it represents a stringent test of drug accumulation and distribution (McGown et al.,

Fig. 2. Immunoblots of p27/kip1 in A549 monolayers and CultiSpheres. A549 cells were grown as monolayers or in CultiSpheres and treated with 10 μg/ml cisplatin. Whole cell lysates were prepared from cells before treatment (M, mock) at 1 h and at 72 h after treatment. Duplicate aliquots of each lysate were probed with p27 antibody. Times of exposure of immunoblots to film were 5 min and 30 min for monolayers and CultiSpheres, respectively. Clonogenic survival of cells used to make cell lysates is shown in Fig. 3A.
Cells were incubated with 5 μg/ml doxorubicin for 1 h at 37°C, released by trypsin or collagenase treatment, and washed free of drug using ice-cold growth medium to prevent doxorubicin diffusion. Doxorubicin epifluorescence was measured in duplicate samples by flow cytometry (McGown et al., 1983; Luk and Tannock, 1989). The flow cytometry data (Fig. 4) shows that when normalized to autofluorescence the shift in mean fluores-

Fig. 3. Clonogenic survival assay results for A549 and KB-3-1 cells grown as monolayers or in CultiSphers. Cells were treated for 1 h with cisplatin, 4-HC, and doxorubicin or for 24 h with paclitaxel. Data are represented as mean ± S.D. of three to six replicates from at least two separate experiments. Values for A549 monolayers at 5 and 20 μg/ml and A549 CultiSphers at 20 μg/ml cisplatin represent triplicates from a single trial. Error bars are concealed within data point size for some values. A, A549 cells treated with cisplatin. B, A549 cells treated with 4-HC. C, A549 cells treated with paclitaxel. D, A549 cells treated with doxorubicin. E, KB-3-1 cells treated with cisplatin. F, Effect of plating cells from CultiSphers onto gelatin-coated monolayers for 4 or 24 h before cisplatin treatment. Cells were treated as CultiSphers or plated for 4 or 24 h as monolayers before treatment with the indicated doses of cisplatin. Data are representative of two separate experiments.
cence following doxorubicin treatment was about 2-fold greater for cells in CultiSphers compared with cells in monolayer. These data suggest that cells in CultiSphers accumulated more, not less, doxorubicin than cells in monolayers in this experiment. In repeated experiments, cells in CultiSphers never had lower mean fluorescence than cells in monolayers, indicating that cells in CultiSphers and monolayers had at least equal doxorubicin uptake. Furthermore, the shapes of the histograms for the accumulation of doxorubicin were very similar (Fig. 4), suggesting that the distribution of doxorubicin, on a per cell basis, was similar in cells treated in monolayers and in CultiSphers.

Second, to confirm that Pt-DNA adduct formation was comparable in monolayers and CultiSphers, atomic absorption spectroscopy was performed using isolated DNA. Pt-DNA adduct formation following 1 h of treatment with 10 μg/ml cisplatin in A549 cells grown as monolayers and in CultiSphers is shown in Table 1. Essentially equivalent amounts of Pt-DNA adduct formation were observed. However, the ability of atomic absorption spectroscopy to accurately measure low levels of Pt-DNA adducts is limited and true equivalency at this adduct level could not be concluded. Therefore, A549 cells grown as monolayers and in CultiSphers were treated with 10 or 40 μg/ml cisplatin for 4 h to increase total Pt-DNA adduct formation and assure measurement accuracy (Table 1). In this second experiment, as in the first, A549 cells in monolayers and CultiSphers accumulated essentially equivalent amounts of Pt-DNA adducts per microgram DNA.

**Role of p53 in Response to Cisplatin Treatment in Cells Grown in CultiSphers and Monolayers.** The decreased sensitivity of response to DNA damage by cisplatin of cells grown in CultiSphers (Fig. 3) suggested that levels of DNA damage recognition and response proteins, such as p53, might be different in cells in the two growth conditions. To examine this possibility, cell lines that differed in p53 expression were used. Derivatives of the parental A549 human lung tumor cell line, A549/LXSN, and A549/16E6, as well as the p53 null line NCI-H1299, were grown as monolayers and

<table>
<thead>
<tr>
<th>Sample</th>
<th>Cisplatin (μg/ml)</th>
<th>Time (hr)</th>
<th>Pt-DNA adduct formation (pg Pt/100 μg DNA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monolayer</td>
<td>10</td>
<td>1</td>
<td>5.4 ± 2.9</td>
</tr>
<tr>
<td>CultiSpher</td>
<td>10</td>
<td>1</td>
<td>5.3 ± 1.5</td>
</tr>
<tr>
<td>Monolayer</td>
<td>10</td>
<td>4</td>
<td>24.0 ± 2.1</td>
</tr>
<tr>
<td>CultiSpher</td>
<td>10</td>
<td>4</td>
<td>27.2 ± 0.3</td>
</tr>
<tr>
<td>Monolayer</td>
<td>40</td>
<td>4</td>
<td>120.3 ± 4.2</td>
</tr>
<tr>
<td>CultiSpher</td>
<td>40</td>
<td>4</td>
<td>144.4 ± 26.2</td>
</tr>
</tbody>
</table>

**Table 1**

Cisplatin adduct levels in A549 monolayers and CultiSphers

Pt-DNA adduct formation and platinum accumulation in A549 cells monolayers and CultiSphers using atomic absorption spectroscopy (AAS). Mean value and standard error calculated from two separate trials.

Fig. 4. Doxorubicin epifluorescence assayed by flow cytometry. A549 cells grown as monolayers or in CultiSphers were treated without (−Dox) or with 5 μg/ml doxorubicin (+Dox) for 1 h at 37°C. Following release from monolayers and CultiSphers, cellular doxorubicin accumulation was assayed. Cell volume (forward and side scatter) was used to determine population of cells in which fluorescence was measured with a single gate applied to all samples. Autofluorescence (−Dox) or doxorubicin fluorescence (+Dox) was determined in duplicate samples (rows 1 and 2) from a single experiment. M1 indicates statistical marker for determination of mean fluorescence.
CultiSpheres and then treated with cisplatin. A549/LXSN cells, containing an empty retroviral vector, have similar, low basal levels of p53 expression when grown both as monolayers and in CultiSpheres (data not shown). A549/16E6 cells contain a retroviral vector expressing the human papilloma virus strain 16 E6 protein, which abrogates wild-type p53 function by facilitating its degradation via the ubiquitin pathway (Scheffner et al., 1990; Butz et al., 1995; Rolfe et al., 1995). The absence of p53 protein in the A549/16E6 cell line was confirmed by Western blot analysis (data not shown) before the clonogenic experiments described below.

The cisplatin sensitivity of A549/LXSN and A549/16E6 cells was examined following growth in monolayers and CultiSpheres. A549/LXSN cells had identical sensitivity to cisplatin as the A549 parental line (data not shown). The results shown in Fig. 5A indicate that A549/16E6 cells were less sensitive to cisplatin, both as monolayers and in CultiSpheres, than A549/LXSN or A549 parental cells (Fig. 3A) grown in identical fashions. To further verify that decreased sensitivity to cisplatin of cells in CultiSpheres was independent of p53 status, the sensitivity of p53 null human lung tumor cell line NCI-H1299 was examined. As shown in Fig. 5B, NCI-H1299 cells grown in CultiSpheres were less sensitive to cisplatin than the same cells grown as monolayers. Statistical analysis using Student’s t test at 15 μg/ml cisplatin showed significantly different survival fractions for cells grown as monolayers versus in CultiSpheres (P < .0001 for A549/LXSN and A549/16E6 cells in Fig. 5A and for NCI-H1299 cells in Fig. 5B).

**Cell Cycle Response to Drug-Induced Damage in Cells Grown in CultiSpheres and Monolayers.** Cisplatin treatment induces G2/M cell cycle arrest (Sorenson and Eastman, 1988; Rolfe et al., 1995) in many, but not all, cell types containing wild-type p53 (Sorenson et al., 1990; Fan et al., 1994, 1995; Fujiwara et al., 1994; Hawkins et al., 1996; Kawasaki et al., 1996). To determine whether growth conditions altered this response, asynchronous cultures of A549/LXSN and KB-3-1 cells grown as monolayers and in CultiSpheres were treated with 10 μg/ml cisplatin for 1 h, washed, allowed to recover in situ, and then serially harvested for flow cytometry analysis for up to 120 h after treatment. Aggregate data from 10 separate cell cycle experiments indicate that S phase fractions for monolayers (31.77 ± 18.11%) and CultiSpheres (22.89 ± 15.27%) are not statistically significant from each other using Student’s t test (P = .71). This suggests that cell cycle profiles at the time of drug treatment for monolayers and CultiSpheres are not significantly different. As shown in Fig. 6, by 48 h after treatment both A549/LXSN monolayers (Fig. 6A) and KB-3-1 monolayers (Fig. 6B) exhibit a G2 arrest that continues until at least 96 to 120 h post-treatment. However, a prolonged G2/M arrest of A549 cells grown as monolayers following cisplatin treatment was not observed in every experiment, and did not correlate well with cell survival (data not shown). When either A549/LXSN or KB-3-1 cells were grown in CultiSpheres and treated with cisplatin, a portion of the cells appear to remain in G1. Between 72 to 120 h after cisplatin treatment the proportion of cells in G1 increased relative to 48 h, suggesting that some cells progress past G2/M and arrest in G1. In addition, no sub-G1 DNA content, an indicator of apoptosis, was observed following treatment of A549 or KB-3-1 cells with cisplatin. It should be further noted that neither A549 nor KB-3-1 cells respond to cisplatin, at the doses used in these studies, by undergoing classical apoptosis (no sub-G1 DNA content, minimal poly(ADP)ribose polymerase cleavage, minimal DNA laddering, minimal annexin V binding (M. Ihnat and M.M. Cornwell unpublished observations).

The cell cycle response of A549 cells to paclitaxel treatment is shown in Fig. 6C. Cells were treated with 33 nM paclitaxel for 24 h, conditions that resulted in cell survival similar to 10 μg/ml cisplatin. Following 24 h of paclitaxel treatment, A549 monolayers exhibited a pronounced G2/M arrest. By 48 h following treatment, cells in monolayers displayed a considerable fraction of cells with sub-G1 DNA, an indicator of apoptosis. The sub-G1 content of cells in monolayers increased at 72 and 96 h postpaclitaxel treatment. Similar to cells in monolayer, A549 cells grown in CultiSpheres accumulated in G2/M following paclitaxel treatment for 24 h. In contrast to cells in monolayers, the sub-G1 content of cells in CultiSpheres did not increase substantially until 72 and 96 h postpaclitaxel treatment, and the fraction of cells with the expected G2/M arrest did not increase.

---

**Fig. 5.** Clonogenic survival assay results for A549/LXSN, A549/16E6, and NCI-H1299 cells. Cells grown as monolayers or in CultiSpheres were treated with cisplatin. A, A549/LXSN and A549/16E6 cells were treated for 1 h with cisplatin. Data represent mean ± S.D. of three to six individual samples from a single experiment.
sub-G1 DNA content was lower than in paclitaxel-treated monolayers.

**Discussion**

These studies suggest that the growth of human cancer cell lines in macroporous, microcarrier beads can alter their response to cancer chemotherapeutic agents compared with growth as dispersed monolayer culture. We have previously demonstrated that cells in CultiSphers exhibit substantial three-dimensional contact without central necrosis and lack an edge-to-center gradient of proliferation or evidence of a hypoxic fraction (Rasey et al., 1996).

In the present work, we demonstrate that cells in Culti-Sphers can be grown with similar cell cycle profiles as monolayers under conditions in which similarly low levels of the cell cycle inhibitor p27kip1, which causes cell cycle arrest, are expressed. In our studies, cells grown as monolayers lacking p53 (A549/16E6, NCI-H1299) are less sensitive to cisplatin treatment when compared with similar cells with an intact p53 (A549, A549/LXSN). Cells lacking p53 function have been shown to have increased (Hawkins et al., 1996) as well as decreased (Piovesan et al., 1998) sensitivity to cisplatin, thus the role of p53 in drug resistance has yet to be fully understood. Furthermore, three human epithelial-derived cancer cell lines with differing p53 status (wild-type, E6-expressing, and null) all demonstrate significantly altered drug responses in CultiSpher compared with monolayer culture. These data suggest that the decreased cisplatin sensitivity of cells in CultiSphers is p53-independent. In addition, altered responses to drug treatment are observed under culture conditions that produce similar growth and drug distribution.

---

**Fig. 6.** Fluorescence histograms for A549/LXSN cells (A), KB-3-1 cells (B), and A549 cells (C) grown as monolayers or in CultiSphers, treated for 1 h with 10 μg/ml cisplatin (A and B) or paclitaxel (C). At indicated times following treatment cells were ethanol fixed, incubated with propidium iodide, and analyzed by flow cytometry. Cell cycle profiles for A549 parental cells after treatment with cisplatin were identical with A549/LXSN (data not shown).
Determining equivalent drug uptake in cells grown in monolayers and CultiSpheres is crucial, because it is known that multicellular growth can alter the total accumulation of drug per cell by causing drug gradients (Durand, 1990; Erlichman and Wu, 1992; Johnson et al., 1994; Ramachandran et al., 1995). We use two approaches to document that drug distribution is comparable in cells grown in monolayers and CultiSpheres. First, we demonstrate using doxorubicin epifluorescence that cells in monolayers and CultiSpheres have similar drug distribution histograms. This indicates that, unlike cells grown in spheroids (Sutherland et al., 1979; Sakata et al., 1994), all the cells in the CultiSpheres accumulate doxorubicin to a similar degree and to at least an amount comparable with cells grown as monolayers. Second, we demonstrate that cells in monolayers and CultiSpheres form similar amounts of Pt-DNA adducts as monolayer cultures. Thus, differences in Pt-adduct formation are not likely to account for the observed differences in drug sensitivity. These data also suggest that cellular mechanisms that alter postuptake cisplatin metabolism (such as altered glutathione levels and multidrug resistance protein pump activity) do not account for the decreased drug sensitivity of cells in CultiSpheres.

We report that cells grown in CultiSpheres at the time of treatment with chemotherapeutic agents express very little p27/kip1, a mediator of cell cycle arrest (Polyak et al., 1994). This contrasts with studies using multicellular spheroids as a model, in which increased p27 expression has been correlated with decreased drug sensitivity (St. Croix et al., 1996a). Thus, we believe that the decreased drug sensitivity observed with cells grown in CultiSpheres is not due to an arrested population of cells as a result of growth in three dimensions, as is the case with cells grown as multicellular spheroids.

We also did not find an obvious correlation between cell cycle response and clonogenic survival in monolayer versus CultiSpher cultures after cisplatin treatment. Although the majority of A549 cells and all KB-3-1 monolayer cells enter a prolonged G2/M arrest by 48 h after 10 μg/ml cisplatin treatment, A549 cells in monolayers do not always remain in G2/M at longer time points following treatment. However, when A549 or KB-3-1 cells are grown in CultiSpheres before cisplatin treatment, in every experiment a portion of both cells fail to exit G1, while some cells progress past G2/M. Thus, with asynchronous A549 cultures, a clear correlation cannot be made between decreased sensitivity of cells in CultiSpheres and cell cycle response following cisplatin treatment. Experiments using synchronous cell populations to further investigate the altered cell cycle response of cells in CultiSpheres are in progress.

Through immunoblot analysis of proteins associated with apoptosis and markers of apoptotic cell death, we found that 10 μg/ml cisplatin treatment for 1 h does not kill A549 cells through classical apoptotic pathways (data not shown). It was further observed that many A549 cells remain attached to cell culture dishes following 10 μg/ml cisplatin treatment but do not proliferate to form colonies (data not shown). To confirm that cisplatin-treated cells from both growth modes were viable post-treatment, equal numbers of cells from A549 monolayers and CultiSpheres were plated after a 1 h cisplatin treatment and then assayed for viability using the 3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxy methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) cell dehydrogenase assay or by trypan blue staining. At 48 and 72 h post-treatment, no difference in MTS dehydrogenase activity or trypan blue dye exclusion was observed following treatment of cells in monolayers and CultiSpheres (data not shown). Thus, we speculate that growth of cells in CultiSpheres increases the ability of cisplatin-treated cells to proliferate rather than induces the cells to die. If correct, the effect of cisplatin on proliferation rather than viability may account for the observations made by Frankel et al. (1997) in which no difference in cisplatin sensitivity between cells grown as monolayers and multicellular spheroids was observed. In that study the sensitivity of cisplatin-treated cells was measured by MTS and [3H]thymidine incorporation, not by clonogenic cell survival.

The sensitivities to chemotherapeutic drugs that form DNA adducts (cisplatin and 4-HC), intercalate into DNA, and alter cellular membranes (doxorubicin), as well as to an agent that does not directly adduct DNA (paclitaxel), are all decreased by multicellular growth in CultiSpheres. Thus, it is possible that the decreased drug sensitivities of cells grown in CultiSpheres relative to monolayers are independent of drug mechanism of action. The decreased sensitivity to paclitaxel of cells grown in CultiSpheres compared with monolayers suggests that this phenotype is not solely related to augmented DNA repair of drug-induced lesions. In addition, the observation that paclitaxel induces sub-G1 content (an indicator of apoptosis) in A549 monolayers and CultiSpheres, whereas cisplatin does not, also suggests that decreased drug sensitivity of cells grown in CultiSpheres is not due to a defect in the apoptotic pathway, but rather to a qualitative change in apoptotic response.

Although it is probable that there are distinct drug-specific pathways within the cellular damage response signaling network, we speculate that a set of common events occurring before drug treatment, dependent on multicellular growth, alters the cellular damage response through specific signaling pathways. Data suggesting that the CultiSpher resistance phenotype is reversed or lost after replating cells for 24 h but not for 4 h, before drug treatment supports our speculation that growth conditions before drug exposure determine the clonogenic survival of cells. Our current working hypothesis is that multicellular growth of cells in CultiSpheres activates survival factor signaling networks (Evan et al., 1995), which in turn inhibit drug-induced cell death signals and promote cell proliferation.

Our aim was to develop a model in vitro culture system that is similar to three-dimensional cellular contact in vivo while retaining the advantages of homogeneous, comparable, easily manipulated cell populations for molecular analysis. We demonstrated that extensive cell-cell contact exists in CultiSpheres in a cell population that is similar to dispersed monolayers in several important parameters, especially comparable cell cycle transit time and drug uptake. We are currently investigating whether growth in CultiSpheres alters drug response by facilitating cell-cell interactions, and thereby the formation of gap junctions, extracellular matrix deposition, and ligand-receptor interaction, etc., or whether changes in drug response are independent of cell-cell contact. In summary, this work demonstrates that the growth of cells in CultiSpheres provides a relatively simple and useful model system with advantages over monolayer culture to advance the molecular characterization of cell contact-induced drug resistance.
Multicellular Growth-Induced Changes in Drug Resistance


Send reprint requests to: Dr. Marilyn L. Cornwell, Fred Hutchinson Cancer Center, Mail Stop D2–100, 1100 Fairview Ave. N., Seattle, WA 98109. E-mail: mcornwel@fhcrc.org